|
| Incidence | Cost data (CNY) | Management mode | DSA | PSA | Remark | |
| APP | PP | ||||||
| Neutrophil count decreased | 22.9% | 19.2% | 3080 | thiopefilgrastim 6 mg, 1080/6mg * 1 | ±25% | GAMMA | Jiangsu Hengrui Pharmaceutical |
| White blood cell count decreased | 14.6% | 9.6% | 3080 | thiopefilgrastim 6 mg, 1080/6mg * 1 | ±25% | GAMMA | Jiangsu Hengrui Pharmaceutical |
| Anemia | 6.3% | 13.5% | 420 | red blood cell suspension 2U, 210/1U | ±25% | GAMMA | [17] |
| Platelet count decreased | 8.3% | 7.7% | 1820 | Recombinant Human Interleukin- 11,130/1.5mg/day, 14d of treament | ±25% | GAMMA | Qilu Pharmaceutical |